Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Geron (NASDAQ: GERN ) had a rough go of it over the last two years, as shares have lost over 70% of their value. The company controversially sold off its stem-cell business to focus on hot cancer drug candidate imetelstat. If imetelstat were a success, management would look brilliant for backing the right horse while avoiding the stem cell R&D black hole. Unfortunately, that proved to be a big if. Imetelstat's Phase 2 trial for breast cancer was cancelled, and Geron decided not to advance it to Phase 3 in NSCLC.
As Geron presses ahead with imetelstat, it is losing support from Wall Street. A Stifel Nicolaus analyst ripped the company's plans apart, calling them "flawed and sluggish," while dropping its rating all the way to sell.
Watch and find out what Motley Fool health-care analyst David Williamson thinks about Geron's downgrade, and what it means for investors.
What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness?" Find out in our free report, What's Really Eating at America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.